Molecular analysis of pediatric oligodendrogliomas highlights genetic differences with adult counterparts and other pediatric gliomas

Brain Pathology

Volumn 26, Issue 2, 2016, Pages 206-214

  Nauen, David ^a   Haley, Lisa ^a   Lin, Ming Tseh ^a   Perry, Arie ^b   Giannini, Caterina ^c   Burger, Peter C ^a   Rodriguez, Fausto J ^a  

^a JOHNS HOPKINS HOSPITAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Mayo Clinic College of Medicine   (United States)

Author keywords

BRAF; cytogenetics; FISH; oligodendroglioma; pediatric glioma; SNP array

Indexed keywords

B RAF KINASE; PROTEIN MDM2; BRAF PROTEIN, HUMAN;

ADULT; ARTICLE; CHILD; CHILDHOOD CANCER; CHROMOSOME 13Q; CHROMOSOME 14Q; CHROMOSOME 17P; CHROMOSOME 17Q; CHROMOSOME 18; CHROMOSOME 3Q; CHROMOSOME 4Q; CHROMOSOME 6P; CHROMOSOME DELETION; CONTROLLED STUDY; CYTOGENETICS; GENE DELETION; GENETIC ANALYSIS; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; OLIGODENDROGLIOMA; SINGLE NUCLEOTIDE POLYMORPHISM; UNIPARENTAL DISOMY; ADOLESCENT; BRAIN; BRAIN TUMOR; CANCER GRADING; DNA MUTATIONAL ANALYSIS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENETICS; IMMUNOHISTOCHEMISTRY; INFANT; MALE; METABOLISM; PATHOLOGY; PRESCHOOL CHILD; YOUNG ADULT;

ADOLESCENT; BRAIN; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; INFANT; LOSS OF HETEROZYGOSITY; MALE; NEOPLASM GRADING; OLIGODENDROGLIOMA; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTO-ONCOGENE PROTEINS B-RAF; SEQUENCE DELETION; YOUNG ADULT;

EID: 84939244139     PISSN: 10156305     EISSN: 17503639     Source Type: Journal    
DOI: 10.1111/bpa.12291     Document Type: Article

References (44)

1. Agamanolis DP, Katsetos CD, Klonk CJ, Bartkowski HM, Ganapathy S, Staugaitis SM, et al (2012) An unusual form of superficially disseminated glioma in children: report of 3 cases. J Child Neurol 27: 727-733.
2. Bai R, Shi Z, Zhang JW, Li D, Zhu YL, Zheng S, (2012) ST13, a proliferation regulator, inhibits growth and migration of colorectal cancer cell lines. J Zhejiang Univ Sci B 13: 884-893.
3. Bar EE, Lin A, Tihan T, Burger PC, Eberhart CG, (2008) Frequent gains at chromosome 7q34 involving BRAF in pilocytic astrocytoma. J Neuropathol Exp Neurol 67: 878-887.
4. Bettegowda C, Agrawal N, Jiao Y, Sausen M, Wood LD, Hruban RH, et al (2011) Mutations in CIC and FUBP1 contribute to human oligodendroglioma. Science 333: 1453-1455.
5. Blesa D, Mollejo M, Ruano Y, de Lope AR, Fiano C, Ribalta T, et al (2009) Novel genomic alterations and mechanisms associated with tumor progression in oligodendroglioma and mixed oligoastrocytoma. J Neuropathol Exp Neurol 68: 274-285.
6. Cairncross G, Wang M, Shaw E, Jenkins R, Brachman D, Buckner J, et al (2013) Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol 31: 337-343.
7. Chappe C, Padovani L, Scavarda D, Forest F, Nanni-Metellus I, Loundou A, et al (2013) Dysembryoplastic neuroepithelial tumors share with pleomorphic xanthoastrocytomas and gangliogliomas BRAF(V600E) mutation and expression. Brain Pathol 23: 574-583.
8. Elexpuru-Camiruaga J, Buxton N, Kandula V, Dias PS, Campbell D, McIntosh J, et al (1995) Susceptibility to astrocytoma and meningioma: influence of allelism at glutathione S-transferase (GSTT1 and GSTM1) and cytochrome P-450 (CYP2D6) loci. Cancer Res 55: 4237-4239.
9. Gielen GH, Gessi M, Buttarelli FR, Baldi C, Hammes J, Zur Muehlen A, et al (2015) Genetic analysis of diffuse high-grade astrocytomas in infancy defines a novel molecular entity. Brain Pathol 25: 409-417.
10. Gorovets D, Kannan K, Shen R, Kastenhuber ER, Islamdoust N, Campos C, et al (2012) IDH mutation and neuroglial developmental features define clinically distinct subclasses of lower grade diffuse astrocytic glioma. Clin Cancer Res 18: 2490-2501.
11. Griffin CA, Burger P, Morsberger L, Yonescu R, Swierczynski S, Weingart JD, Murphy KM, (2006) Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests mechanism of concurrent 1p and 19q loss. J Neuropathol Exp Neurol 65: 988-994.
12. Harada S, Henderson LB, Eshleman JR, Gocke CD, Burger P, Griffin CA, Batista DA, (2011) Genomic changes in gliomas detected using single nucleotide polymorphism array in formalin-fixed, paraffin-embedded tissue: superior results compared with microsatellite analysis. J Mol Diagn 13: 541-548.
13. Hartmann C, Numann A, Mueller W, Holtkamp N, Simon M, von Deimling A, (2004) Fine mapping of chromosome 22q tumor suppressor gene candidate regions in astrocytoma. Int J Cancer 108: 839-844.
14. Horbinski C, Nikiforova MN, Hobbs J, Bortoluzzi S, Cieply K, Dacic S, Hamilton RL, (2012) The importance of 10q status in an outcomes-based comparison between 1p/19q fluorescence in situ hybridization and polymerase chain reaction-based microsatellite loss of heterozygosity analysis of oligodendrogliomas. J Neuropathol Exp Neurol 71: 73-82.
15. Ida CM, Vrana JA, Rodriguez FJ, Jentoft ME, Caron AA, Jenkins SM, Giannini C, (2013) Immunohistochemistry is highly sensitive and specific for detection of BRAF V600E mutation in pleomorphic xanthoastrocytoma. Acta Neuropathol Commun 1: 20.
16. Jenkins RB, Blair H, Ballman KV, Giannini C, Arusell RM, Law M, et al (2006) A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res 66: 9852-9861.
17. Jenkins RB, Xiao Y, Sicotte H, Decker PA, Kollmeyer TM, Hansen HM, et al (2012) A low-frequency variant at 8q24.21 is strongly associated with risk of oligodendroglial tumors and astrocytomas with IDH1 or IDH2 mutation. Nat Genet 44: 1122-1125.
18. Kelsey KT, Wrensch M, Zuo ZF, Miike R, Wiencke JK, (1997) A population-based case-control study of the CYP2D6 and GSTT1 polymorphisms and malignant brain tumors. Pharmacogenetics 7: 463-468.
19. Kim YH, Lachuer J, Mittelbronn M, Paulus W, Brokinkel B, Keyvani K, et al (2011) Alterations in the RB1 pathway in low-grade diffuse gliomas lacking common genetic alterations. Brain Pathol 21: 645-651.
20. Kitange G, Misra A, Law M, Passe S, Kollmeyer TM, Maurer M, et al (2005) Chromosomal imbalances detected by array comparative genomic hybridization in human oligodendrogliomas and mixed oligoastrocytomas. Genes Chromosomes Cancer 42: 68-77.
21. Koschny R, Koschny T, Froster UG, Krupp W, Zuber MA, (2002) Comparative genomic hybridization in glioma: a meta-analysis of 509 cases. Cancer Genet Cytogenet 135: 147-159.
22. Kreiger PA, Okada Y, Simon S, Rorke LB, Louis DN, Golden JA, (2005) Losses of chromosomes 1p and 19q are rare in pediatric oligodendrogliomas. Acta Neuropathol 109: 387-392.
23. Kros JM, van Run PR, Alers JC, Beverloo HB, van den Bent MJ, Avezaat CJ, van Dekken H, (1999) Genetic aberrations in oligodendroglial tumours: an analysis using comparative genomic hybridization (CGH). J Pathol 188: 282-288.
24. Kumar A, Pathak P, Purkait S, Faruq M, Jha P, Mallick S, et al (2015) Oncogenic KIAA1549-BRAF fusion with activation of the MAPK/ERK pathway in pediatric oligodendrogliomas. Cancer Genet 208: 91-95.
25. Mistry M, Zhukova N, Merico D, Rakopoulos P, Krishnatry R, Shago M, et al (2015) BRAF mutation and CDKN2A deletion define a clinically distinct subgroup of childhood secondary high-grade glioma. J Clin Oncol 33: 1015-1022.
26. Mohapatra G, Engler DA, Starbuck KD, Kim JC, Bernay DC, Scangas GA, et al (2011) Genome-wide comparison of paired fresh frozen and formalin-fixed paraffin-embedded gliomas by custom BAC and oligonucleotide array comparative genomic hybridization: facilitating analysis of archival gliomas. Acta Neuropathol 121: 529-543.
27. Nakamura M, Shimada K, Ishida E, Higuchi T, Nakase H, Sakaki T, Konishi N, (2007) Molecular pathogenesis of pediatric astrocytic tumors. Neuro-Oncol 9: 113-123.
28. Nauen DW, Guajardo A, Haley L, Powell K, Burger PC, Gocke CD, (2015) Chromosomal defects track tumor subpopulations and change in progression in oligodendroglioma. Convergent Sci Phys Oncol (adv online pub).
29. Padovani L, Colin C, Fernandez C, Maues de Paula A, Mercurio S, Scavarda D, et al (2012) Search for distinctive markers in DNT and cortical grade II glioma in children: same clinicopathological and molecular entities? Curr Top Med Chem 12: 1683-1692.
30. Perilongo G, Gardiman M, Bisaglia L, Rigobello L, Calderone M, Battistella A, et al (2002) Spinal low-grade neoplasms with extensive leptomeningeal dissemination in children. Childs Nerv Syst 18: 505-512.
31. Raghavan R, Balani J, Perry A, Margraf L, Vono MB, Cai DX, et al (2003) Pediatric oligodendrogliomas: a study of molecular alterations on 1p and 19q using fluorescence in situ hybridization. J Neuropathol Exp Neurol 62: 530-537.
32. Reifenberger G, Reifenberger J, Ichimura K, Meltzer PS, Collins VP, (1994) Amplification of multiple genes from chromosomal region 12q13-14 in human malignant gliomas: preliminary mapping of the amplicons shows preferential involvement of CDK4, SAS, and MDM2. Cancer Res 54: 4299-4303.
33. Reis GF, Pekmezci M, Hansen HM, Rice T, Marshall RE, Molinaro AM, et al (2015) CDKN2A loss is associated with shortened overall survival in lower-grade (World Health Organization Grades II-III) astrocytomas. J Neuropathol Exp Neurol 74: 442-452.
34. Rodriguez FJ, Perry A, Rosenblum MK, Krawitz S, Cohen KJ, Lin D, et al (2012) Disseminated oligodendroglial-like leptomeningeal tumor of childhood: a distinctive clinicopathologic entity. Acta Neuropathol 124: 627-641.
35. Rodriguez FJ, Tihan T, Lin D, McDonald W, Nigro J, Feuerstein B, et al (2014) Clinicopathologic features of pediatric oligodendrogliomas: a series of 50 patients. Am J Surg Pathol 38: 1058-1070.
36. Rodriguez FJ, Schniederjan MJ, Nicolaides T, Tihan T, Burger PC, Perry A, (2015) High rate of concurrent BRAF-KIAA1549 gene fusion and 1p deletion in disseminated oligodendroglioma-like leptomeningeal neoplasms (DOLN). Acta Neuropathol 129: 609-610.
37. Rossi MR, Gaile D, Laduca J, Matsui S, Conroy J, McQuaid D, et al (2005) Identification of consistent novel submegabase deletions in low-grade oligodendrogliomas using array-based comparative genomic hybridization. Genes Chromosomes Cancer 44: 85-96.
38. Schniederjan MJ, Alghamdi S, Castellano-Sanchez A, Mazewski C, Brahma B, Brat DJ, et al (2013) Diffuse leptomeningeal neuroepithelial tumor: 9 pediatric cases with chromosome 1p/19q deletion status and IDH1 (R132H) immunohistochemistry. Am J Surg Pathol 37: 763-771.
39. Suri V, Jha P, Agarwal S, Pathak P, Sharma MC, Sharma V, et al (2011) Molecular profile of oligodendrogliomas in young patients. Neuro-Oncol 13: 1099-1106.
40. Talagas M, Marcorelles P, Uguen A, Redon S, Quintin-Roue I, Costa S, et al (2012) Identification of a novel population in high-grade oligodendroglial tumors not deleted on 1p/19q using array CGH. J Neurooncol 109: 405-413.
41. van den Bent MJ, Brandes AA, Taphoorn MJ, Kros JM, Kouwenhoven MC, Delattre JY, et al (2013) Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol 31: 344-350.
42. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, et al (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360: 765-773.
43. Yip S, Butterfield YS, Morozova O, Chittaranjan S, Blough MD, An J, et al (2012) Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers. J Pathol 226: 7-16.
44. Zhang J, Wu G, Miller CP, Tatevossian RG, Dalton JD, Tang B, et al (2013) Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas. Nat Genet 45: 602-612.